School of Medicine
Showing 1-50 of 132 Results
-
Deborah Alcorn, MD
Associate Professor of Ophthalmology at the Stanford University Medical Center, Emerita
Current Research and Scholarly InterestsGene linkage - tuberous sclerosis; stabismus and, molteno implants; congenital stationary night blindness
-
Tayyeba K. Ali, MD
Adjunct Clinical Associate Professor, Ophthalmology
BioTayyeba K. Ali, MD, a Board Certified ophthalmologist, specializes in complex corneal disease and uveitis. She sees patients at Palo Alto Medical Foundation / Sutter Health in Sunnyvale, CA. Dr. Ali also works as a medical specialist on contract for Google.
Prior to completing two fellowships in cornea, external disease, refractive surgery and uveitis at Bascom Palmer Eye Institute, ranked #1 eye hospital in the United States by U.S. News & World Report, Dr. Ali finished her ophthalmology residency at the Jones Eye Institute / UAMS. She earned her medical degree from Emory University School of Medicine and completed her undergraduate training in English literature and creative writing from Agnes Scott College.
Dr. Ali has received many academic and teaching awards including the Bascom Palmer Fellow of the Year Award and the Jone’s Eye Dean’s Faculty Award. She has delivered dozens of lectures on the national and international level and published numerous meeting abstracts and peer-reviewed journal articles.
As a second generation American, Tayyeba finds herself dwelling on migrant and refugee stories, their need for ethnic and religious identity, and the repercussions of these journeys. She is keenly interested in international medicine, resident education, health technology and taking a closer look at the moral crossroads we face in healthcare. She is the Associated Director for Pegasus Physician Writers at Stanford as well as the Senior Fiction Editor for the medical literary magazine, The Pegasus Review; she has a particular affinity for colons (grammatically, not anatomically, speaking) and semicolons. -
Jill Beyer, OD
Clinical Assistant Professor, Ophthalmology
BioJill Beyer, OD, is a Clinical Assistant Professor at Stanford University School of Medicine.
Dr. Beyer graduated from Southern California College of Optometry, earning her Doctor of Optometry degree with distinction. She completed her residency at New England College of Optometry in Boston, Massachusetts, and earned a Bachelor of Science degree in Biology from Oregon State University.
Jill’s residency education included time spent at the Boston Foundation for Sight, Massachusetts Eye and Ear Infirmary, Cornea Consultants & Boston Laser Center, and Harvard Vanguard Medical Associates.
After residency training, Jill continued on as a clinical preceptor at the New England College of Optometry while working in private practice in Boston. She then transitioned to full time academic work at the Massachusetts Eye and Ear Infirmary becoming the Director of the Contact Lens Department and an Instructor in Ophthalmology at Harvard Medical School. -
Gala Beykin, MD
Clinical Instructor, Ophthalmology
BioDr. Beykin is an ophthalmologist and glaucoma specialist at the Byers Eye Institute at Stanford Health Care. She is also a clinical instructor in the Department of Ophthalmology at Stanford University School of Medicine.
Dr. Beykin completed clinical and surgical training in glaucoma at the Byers Eye Institute. She specializes in caring for patients with all types of ophthalmic conditions, including glaucoma and cataract.
She has expertise in clinical trial design and implementation, and studies novel biomarkers and candidate therapeutics for vision protection and restoration in glaucoma. Her research efforts include numerous clinical trials investigating new therapies for eye conditions. Dr. Beykin has participated in multiple studies evaluating drugs targeting retinal disease such as AMD and diabetes-related vision loss, as well as ongoing clinical trials assessing new treatment strategies for neuroprotection, neuroregeneration and neuroenhancement in glaucoma. These include implants that could potentially stop or slow the progression of and help improve vision.
Dr. Beykin has published her work in numerous peer-reviewed journals, including the British Journal of Ophthalmology and Investigative Ophthalmology & Visual Science. She has presented her work at national and international meetings, including those for the International Symposium on Retinal Degeneration and the Association for Research in Vision and Ophthalmology.
She is a member of the Israeli Ophthalmology Society, the Israeli Society for Eye and Vision Research, and the Association for Research in Vision and Ophthalmology. -
Mark S. Blumenkranz, MD, MMS
H. J. Smead Professor of Ophthalmology, Emeritus
Current Research and Scholarly InterestsClinical Interest and Research
My primary areas of interest are in the diagnosis, medical and surgical treatment of vitreal retinal diseases. These principally include age-related macular degeneration and other diseases of the macula, and tractional syndromes, diabetic retinopathy, and complex forms of retinal detachment. I have been interested in the development of novel technology to diagnose and treat these diseases, including new forms of imaging, laser delivery systems, other microsurgical tools, and new drugs and drug delivery systems that inhibit new blood vessel growth, scarring and intraocular inflammation. I have been actively involved in translational research in the laboratory as well as technology transfer associated with that research for a variety of new therapies that have received FDA clearance and been introduced into clinical practice over the past 30 years.
Administrative and Community Service
I have served on the Board of Directors of a variety of voluntary education and service organizations, including the Corporation of Brown University, multiple scientific advisory boards and various philanthropic and research organizations. -
Robert Chang, MD
Associate Professor of Ophthalmology
Current Research and Scholarly InterestsI'm interested in developing a best in class glaucoma registry, utilizing modern algorithm techniques on imaging, text, and biologic data for precision health predictive analytics in glaucoma diagnosis and treatment, validating new medical devices and technologies, especially portable ones, and working on implementation science
-
Fang Chen (Rosy)
Instructor, Ophthalmology
Current Research and Scholarly InterestsCorneal regeneration via hydrogel-based cell scaffold and cell encapsulation
-
Zheng Chen, OD
Clinical Assistant Professor, Ophthalmology
BioDr. Chen is an optometrist with the Byers Eye Institute and a clinical assistant professor in the Department of Ophthalmology at Stanford University School of Medicine.
Dr. Chen diagnoses and treats a range of eye conditions, including refractive errors, glaucoma, cataracts, and diabetic retinopathy. Her clinical experience is in routine and emergency eye care, pre- and post-surgical eye care, and medical management of eye diseases. She delivers patient-focused care, quickly establishing rapport and working effectively with pediatric, geriatric, and culturally diverse populations.
Dr. Chen is a member of Beta Sigma Kappa, an international optometric honor society. -
E.J. Chichilnisky
John R. Adler Professor, Professor of Neurosurgery and of Ophthalmology and, by courtesy, of Electrical Engineering
Current Research and Scholarly InterestsFunctional circuitry of the retina and design of retinal prostheses
-
Ximena Corso Díaz
Assistant Professor of Ophthalmology
Current Research and Scholarly InterestsWe are interested in unraveling the roles of RNA-binding proteins (RBPs) and regulatory RNAs in retinal development and homeostasis.
RNA-binding proteins mediate functional integration of transcriptional and post-transcriptional machineries influencing various aspects of gene expression and RNA metabolism. Several RBPs have cell-type enriched expression patterns in the retina or cause blinding diseases, however their role in retinal development and function is poorly understood. We have identified several RBPs that interact with the photoreceptor-specific transcription factor NRL and are likely involved in development and homeostasis of this retinal cell-type. We are pursuing the following lines of research:
1) RBPs in retinal development and degeneration. We will study the role of RBPs in regulating retinal development and maintaining homeostasis. We will focus on RBPs enriched in the retina, their interactions with retinal transcription factors like NRL, and their relevance to retinal diseases.
2) RBPs in R-loop regulation in the retina. R-loops are triple-stranded structures created when RNA anneals to one of the strands of the DNA duplex. R-loops have many regulatory roles during gene expression and their dysregulation can be detrimental to genome integrity. We observed that R-loops are dynamic during retinal development and identified key R-loop-associated RBPs that are enriched in rod photoreceptors and that interact with the transcription factor NRL. We will study the role of R-loops and their regulatory RBPs in retinal development and homeostasis.
3) Chromatin-associated regulatory RNAs through the retina lifespan. Chromatin-associated RNAs contribute to the dynamic regulation of gene expression, chromatin structure, and genome organization, playing essential roles in various biological processes, including development, differentiation, and disease. We will study how regulatory RNAs, together with their cognate RBPs, influence expression programs and chromatin dynamics through the retina lifespan. -
Charles DeBoer, MD, PhD
Assistant Professor of Ophthalmology
BioDr. DeBoer is a board-certified, fellowship-trained vitreoretinal surgeon with Stanford Health Care’s Byers Eye Institute and a clinical instructor in the Department of Ophthalmology.
He specializes in retinal and macular diseases, treating a range of conditions such as retinal tears, diabetic retinopathy, retinal vein occlusions, macular pucker, macular hole, macular degeneration, retinal detachment, and other complex retinal conditions. Dr. DeBoer incorporates state-of-the-art treatments in personalized, comprehensive care plans for each of his patients. He is dedicated to training future vitreoretinal surgeons and passionate about helping patients through both direct care and research.
Dr. DeBoer’s scientific background in micro- and nanofabrication, mechanical and electrical engineering, and medicine drives his research interests in implantable devices and surgical instruments. While completing his PhD, Dr. DeBoer co-invented a biomimetic accommodating intraocular lens (IOL) that treats both cataracts and presbyopia.
He continues researching microdevices, focusing on extended drug delivery from the lens capsule and microelectromechanical systems (MEMS)-enabled implantable devices. Dr. DeBoer’s research experience spans topics such as material science, drug delivery, IOL design, microfabrication, 3D printing, and medical device design. He has received grant funding for his work and has 12 patents in the field of ophthalmology.
Dr. DeBoer’s work has been published in peer-reviewed journals, including the American Journal of Ophthalmology. He has authored book chapters and presented to his peers at national and international meetings, including meetings of the American Society of Retina Specialists and the Association for Research in Vision and Ophthalmology.
Dr. DeBoer is a member of the American Academy of Ophthalmology and American Society of Retina Specialists. He is also part of the Society of HEED Fellows and Ronald G. Michels Fellowship Foundation. -
Diana Do, MD
Professor of Ophthalmology
Current Research and Scholarly InterestsDr. Do's research focuses on collaborative clinical trials to investigate novel treatments for retinal vascular diseases and ocular inflammation. She performs research to develop state of the art therapies for age-related macular degeneration, diabetic eye disease, retinal vein occlusion, retinal inflammation, and retinal detachment.
-
Alfredo Dubra, PhD
Professor of Ophthalmology
Current Research and Scholarly InterestsOur lab seeks to help the early diagnosing and monitoring progression of ocular, vascular, neurodegenerative and systemic diseases through novel non-invasive optical ophthalmic imaging. We pursue this goal through a multidisciplinary approach that integrates optics, computer science, vision science, electrical engineering and other engineering disciplines.
-
Peter R. Egbert, MD
Professor of Ophthalmology, Emeritus
Current Research and Scholarly InterestsOcular pathology of shaken baby syndrome
-
Kasra Eliasieh, MD
Clinical Instructor, Ophthalmology
BioDr. Eliasieh is a fellowship-trained, board-certified ophthalmologist at the Stanford Health Care Byers Eye Institute and the Oculoplastic and Orbital Surgery Program. He is also a clinical assistant professor in the Department of Ophthalmology at Stanford University School of Medicine.
Dr. Eliasieh specializes in lacrimal (tear duct) and orbital (eye socket) surgery, eyelid surgery, and brow lifts. His research includes the study of eye changes during aging and how moderate to severe thyroid eye disease responds to tocilizumab, a biologic medication.
Dr. Eliasieh’s writing and research appear in publications including Ophthalmic Plastic and Reconstructive Surgery, Cornea, and Proceedings of the National Academy of Sciences. He has also presented his research at the American Society of Ophthalmic Plastic and Reconstructive Surgery (ASOPRS) Annual Fall Scientific Symposium.
Dr. Eliasieh is a member of ASOPRS and the American Academy of Ophthalmology. -
Ann Caroline Fisher, MD
Clinical Professor, Ophthalmology
BioCaroline Fisher, MD, is a Clinical Professor of Ophthalmology at Stanford University Hospital and Clinics. She specializes in cataract and glaucoma surgery, including minimally invasive glaucoma surgery.
She completed her undergraduate education at Stanford University, obtaining both a Bachelor of Science degree in Biology and a Bachelor of Arts degree in Spanish, with Departmental Honors. She earned her medical degree from Stanford University School of Medicine and then went on to her internship at the University of Pennsylvania Presbyterian Hospital. She completed her ophthalmology residency at NYU/ Manhattan Eye, Ear, Throat Hospital. She then returned to Stanford for her Glaucoma Fellowship.
Dr. Fisher is Director of the Stanford Belize Vision Clinic, dedicated to promoting eye health and care in Belize, and providing an international rotation for Stanford Ophthalmology Residents. She is also an Office of Faculty Development and Diversity Liaison and is currently one of the Stanford Network for Advancement and Promotion (SNAP) Cohort Leaders. Dr. Fisher is the Director of Diversity, Equity, and Inclusion for the Department of Ophthalmology. -
Michael W. Gaynon, MD
Clinical Professor, Ophthalmology
Current Research and Scholarly Interests-Retinal Vascular Disease
-Angiogenesis
-Retinopathy of Prematurity
-Sustained Release Drug Delivery Systems -
Jeffrey Goldberg, MD, PhD
Blumenkranz Smead Professor
Current Research and Scholarly InterestsLab research on molecular mechanisms of survival and regeneration in the visual system; retinal development and stem cell biology; nanoparticles and tissue engineering. Clinical trials in imaging, biomarker development, and neuroprotection and vision restoration in glaucoma and other neurodegenerative diseases.
-
Mary Elizabeth Hartnett, MD
Michael F. Marmor, M.D. Professor of Retinal Science and Disease and Professor of Ophthalmology
BioMary Elizabeth Hartnett, MD, is the Michael F. Marmor, M.D. Professor in Retinal Science and Diseases and is a Professor of Ophthalmology at Stanford University. Dr. Hartnett is the director of Pediatric Retina at Stanford University and principal investigator of a retinal angiogenesis laboratory, in which she studies causes and treatments for diseases including retinopathy of prematurity and age-related macular degeneration. She created the first-ever academic textbook on the subject, Pediatric Retina, in its third edition, which has proven to be an invaluable resource for residents and ophthalmologists internationally.
Dr. Hartnett’s NIH-funded laboratory of vascular biology and angiogenesis has studied mechanisms causing pathology in age-related macular degeneration (AMD) and retinopathy of prematurity (ROP). Her work in AMD has been to understand the mechanisms involved in activation and invasion of choroidal endothelial cells anterior to the RPE in order to maintain vasculature that is physiologic and not damaging beneath the RPE. Her lab has elucidated environmental stressors that lead to scarring in the macula for which no vision improvement is currently possible. The goal is to find methods to prevent the scarring.
Her lab’s work in ROP provided the proof of concept to regulate an angiogenic signaling pathway by inhibiting VEGF to facilitate intraretinal neovascularization as well as to inhibit abnormal extraretinal neovascularization and reduce retinal destruction used in previous treatments. Her work has been translated through clinical trials to lead to new treatments for severe ROP and has represented a paradigm shift in the understanding and treatment of severe ROP.
Dr. Hartnett has received numerous awards, including the Weisenfeld Award, the highest award for clinician-scientists given by the Association for Research in Vision and Ophthalmology (ARVO), in 2018, and is an ARVO Gold Fellow. She received the 2019 Paul Kayser/Retina Research Foundation Global Award, the Macula Society’s 2016 Paul Henkind Award and its 2019 Arnall Patz Medal, the Paul Kayser/RRF Global Award from the PanAmerica Society, and the 2021 Suzanne Veronneau-Troutman Award, the most prestigious award from Women in Ophthalmology. In 2022, she was one of six at the University of Utah to receive a distinguished research award, for Pediatrics and Ophthalmology.
Dr. Hartnett's prolific publication record includes 227 articles in peer-reviewed journals and over 40 book chapters. She has delivered numerous national and international invited lectures. Her long list of professional committee work includes serving as chair of the Publications Committee of ARVO, as a mentor for the ARVO Leadership Development Program, and in leadership positions internationally as chair of the research advisory committees for The Macula Society and the Jack McGovern Coats Disease Foundation as well as Chair of the Credentialing Committee for The Retina Society. She reviews manuscripts for more than 20 eye and science journals and serves on the editorial boards of PlosOne, Molecular Vision, and the American Journal of Ophthalmology. Dr. Hartnett is a Fellow of the American College of Surgeons (FACS) and a Silver and Gold Fellow of the Association for Research in Vision and Ophthalmology (FARVO). -
Yang Hu, MD, PhD
Professor of Ophthalmology
Current Research and Scholarly InterestsThe ultimate goal of the laboratory is to develop efficient therapeutic strategies to achieve CNS neural repair, through promoting neuroprotection, axon regeneration and functional recovery.
More specifically, we study retinal ganglion cell (RGC) and optic nerve in various optic neuropathies including traumatic, glaucomatous and inflammatory optic nerve injuries to fully understand the molecular mechanisms of CNS neurodegeneration and axon regeneration failure. -
Michael S. Kapiloff, MD, PhD
Reinhard Family Professor, Professor (Research) of Ophthalmology and, by courtesy, of Medicine (Cardiovascular Medicine)
Current Research and Scholarly InterestsDr. Michael S. Kapiloff is a faculty member in the Departments of Ophthalmology and Medicine (Cardiovascular Medicine) and a member of the Stanford Cardiovascular Institute. Although Dr. Kapiloff was at one time a Board-Certified General Pediatrician, he is currently involved in full-time basic science and translational research. His laboratory studies the basic molecular mechanisms underlying the response of the retinal ganglion cell and cardiac myocyte to disease. The longstanding interest of his laboratory is the role in intracellular signal transduction of multimolecular complexes organized by scaffold proteins. Recently, his lab has also been involved in the translation of these concepts into new therapies, including the development of new AAV gene therapy biologics for the prevention and treatment of heart failure and for neuroprotection in the eye.
URL to NCBI listing of all published works:
http://www.ncbi.nlm.nih.gov/sites/myncbi/michael.kapiloff.1/bibliography/40252285/public/?sort=date&direction=descending
For more information see Dr. Kapiloff's lab website: http://med.stanford.edu/kapilofflab.html -
Ryan Keenan, OD
Clinical Assistant Professor, Ophthalmology
BioDr. Keenan is a board-certified optometrist with the Stanford Health Care Byers Eye Institute and a clinical assistant professor in the Department of Ophthalmology.
Dr. Keenan diagnoses and treats a wide range of ocular and visual issues, such as vision problems related to stroke, intracranial lesions and tumors, and other neurological conditions. His clinical experience involves recognizing and caring for complex neuro-ophthalmic diseases. These include complications from diseases of the nervous system that adversely affect vision.
Dr. Keenan’s research interests include understanding genetic variations related to progressive weakness of the eye muscles. These conditions range from drooping eyelids to increasing limitations in eye movement.
Dr. Keenan has presented research and clinical findings to his peers at national and regional meetings, including the annual meetings of the American Academy of Optometry and the North American Neuro-Ophthalmology Society. -
Khizer Khaderi MD, MPH
Clinical Associate Professor, Ophthalmology
BioDr. Khizer Khaderi is a Clinical Associate Professor at the Byers Eye Institute at Stanford University. Khaderi is the Founding Director of the Stanford Human Perception Laboratory (HPL) and the Stanford Vision Performance Center (VPC). He also serves as faculty at the Stanford Institute for Human-Centered AI and the Wu Tsai Human Performance Alliance (HPA)
Khaderi is a renowned Neuro-Ophthalmic surgeon, technologist and futurist. Dr. Khaderi is pioneering the field of Symbiotics, defined as the convergence of human science + computer science. Khaderi developed the discipline of Symbiotics following initial interest from CS students interested in his research at the Stanford Human Perception Lab. Symbiotics involves a deep understanding in the principles of human systems and applying these principles computationally, to design and develop the next generation of human-centric technologies, where machines perceive, understand and respond to optimize the human experience. Dr. Khaderi envisions the application of Symbiotic principles as the key to unlocking ambient intelligence.
Khaderi has extensive domain expertise in artificial intelligence (AI), spatial computing (virtual reality (VR), augmented reality (AR), mixed reality (MxR)), wearables, gaming, IoT, Web3, applied neuroscience, human factors, and human-machine interfaces/interaction. His research interests include developing personalized human intelligent systems based on the human brain and sensory systems, developing technologies to optimize human performance, and combining biological and computational principles to expand our capabilities in research, clinical practice, and everyday life. Dr. Khaderi's approach to advance research interests and develop practical applications for everyday use is building technology, companies and collaborative partnerships across academia and industry.
Dr. Khaderi’s experience across industry sectors include consumer electronics, gaming, retail, life science, sports/Esports health care, Pharma, e-commerce, to name a few. He has developed novel technologies in these areas, and generated multiple invention patents. Selected as a “40 under 40”, he contributed to President Obama’s Council of Advisors on Science and Technology regarding vision technology and the aging population. He also advises multiple companies, venture firms and organizations including the Global Esports Federation, Magic Leap, Riot Games, Intel, Activision, Unity, Epic Games, Google, FB, Microsoft, Apple, NBA, Aerie Pharma, the World Health Organization, and the World Bank.
